#United States #New York #Levi Korsinsky #Zenas BioPharma #ZBIO

Attention Zenas BioPharma, Inc. Investors

Investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO) are urged to take action before June 16, 2025. Levi & Korsinsky, LLP has initiated a class action lawsuit related to alleged securities fraud that impacted shareholders. If you have suffered financial losses in Zenas BioPharma, it is crucial to understand your rights and the potential for recovery.

About the Class Action

The class action lawsuit aims to represent individuals who purchased or acquired Zenas BioPharma securities during a specific period linked to the company’s initial public offering in September 2024. Allegedly, the company made false statements regarding its financial stability, creating a misleading narrative around its funding and financial health that may have resulted in notable losses for investors.

Key Allegations

The lawsuit asserts that the defendants made misleading claims regarding:
1. Financial Stability: The company allegedly overstated the time frame in which it could fund its operations through existing cash and expected IPO proceeds.
2. Misleading Public Statements: Public disclosures by the company during the relevant period were found to be materially false and misleading.

This situation raises significant concerns for investors who trusted the company’s assertions regarding its financial viability.

What Should You Do?

If you believe you are eligible for participation in this class action or have experienced losses during the class period, you must act quickly. Levi & Korsinsky recommends reaching out by June 16, 2025, to potentially become a lead plaintiff in the case. Remember, you do not have to serve as a lead plaintiff to qualify for any potential recovery.

No Cost to Participate

One of the more reassuring aspects of this class action is that there are no upfront fees for participants. If you are part of the class, compensation could be provided without any out-of-pocket costs or obligations, making it financially accessible for those affected.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has a solid reputation, having represented investors in complex securities litigation for over two decades. They have achieved settlements exceeding hundreds of millions of dollars for shareholders and are recognized within the industry as a leading firm in this realm. Their expertise positions them well to handle high-stakes cases, making them a reliable choice for those impacted by securities fraud.

Contact Information

For further inquiries or to discuss your case directly, you can reach out to Joseph E. Levi, Esq. or Ed Korsinsky, Esq. at:

• - Address: 33 Whitehall Street, 17th Floor, New York, NY 10004
• - Email: info@zlk.com
• - Phone: (212) 363-7500

Next Steps

Do not wait too long to secure your potential rights as an investor in Zenas BioPharma. Act now by contacting Levi & Korsinsky to understand your options fully and ensure that your voice is heard in this crucial class action lawsuit.